---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-23-000078"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2023-10-18T23:59:59+00:00"
generated_at: "2026-06-09T22:16:05.034542+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ligand acquires 13% interest in soticlestat royalties and milestones from Ovid for $30M

## Summary
- Ligand will pay Ovid $30M for a 13% interest in all royalties and milestones owed to Ovid on soticlestat.
- Soticlestat is in Phase 3 trials for Lennox-Gastaut and Dravet syndromes; Takeda expects regulatory filing in FY2024 (Apr 2024-Mar 2025).
- Ovid eligible for up to $660M in milestones plus tiered royalties (low double-digits to 20%) on global sales if approved.
- Takeda bears all development costs; Ovid has no ongoing obligations or costs.

## SEC filing metadata
- accession: 0000886163-23-000078
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2023-10-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616323000078/0000886163-23-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616323000078/lgnd-20231018.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-23-000078
- JSON: https://secwatch.observer/filing/0000886163-23-000078.json
- Plain text: https://secwatch.observer/filing/0000886163-23-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.